Self-replicating RNA nanoparticle vaccine elicits protective immune responses against SARS-CoV-2Original Article Published on 2023-04-232024-09-05 Journal: Molecular Therapy. Nucleic Acids [Category] update2024, [키워드] anti-RBD IgG antibody germinal center response innate immune signaling liposome-protamine-RNA nanoparticle MT: Oligonucleotides: Therapies and Applications Pseudovirus neutralization SARS-CoV-2 RBD Self-replicating RNA T-cell Response [DOI] 10.1016/j.omtn.2023.04.021 PMC 바로가기 [Article Type] Original Article
Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal studyMulticenter Study Published on 2022-12-012023-07-10 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), [키워드] Antibody Response COVID-19 vaccine immunosuppressive therapy rheumatoid arthritis SARS-CoV-2 T-cell Response [DOI] 10.1016/j.ijid.2022.10.035 PMC 바로가기 [Article Type] Multicenter Study
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccinationArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome addition adenoviral-vectored vaccine antibody AZD1222 binding antibody BNT162b2 booster booster vaccination Booster vaccine comparable Complete coronavirus Coronavirus 2019 COVID-19 demonstrated develop dose Effect enrolled enzyme-linked immunosorbent Heterologous highest immune evasion immune response immunogenicity analysis individual induce interferon-γ Messenger RNA Mild moderate mRNA mRNA vaccine mRNA-1273 mutations NAb titer NAbs neutralization neutralize Neutralizing Neutralizing activity neutralizing antibody observé omicron Omicron variant overcome participant raise receive receiving reduction response Serious Adverse Events significant increase Spike protein T-cell activation T-cell Response T-cell responses vaccination Vaccine waning immunity was recorded were measured [DOI] 10.1002/jmv.28044 PMC 바로가기
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age Analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
A replication-competent smallpox vaccine LC16m8Δ-based COVID-19 vaccineArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome analysed antibody antibody titres BALB/c BALB/c mouse boost CD4 CD8 cellular cellular immunity coronavirus coronavirus disease COVID-19 COVID-19 vaccine Delta/B.1.617.2 variant of concern effective eight elicited emerging and re-Emerging coronaviruses glycoprotein homologous humoral Humoral immunity immunization Japanese LC16m8 less mice motif multifunctional neutralized Neutralizing activity patients with COVID-19 polybasic prime-boost immunization. provide recombinant replication-competent viral S-specific antibody S1/S2 cleavage site SARS-CoV-2 serum sample significantly lower Strains T-cell immune responses T-cell immunity T-cell Response the S protein Vaccine Vaccine development vaccine platform variant vector viral vectors virus Wuhan [DOI] 10.1080/22221751.2022.2122580 PMC 바로가기
Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccinesCOVID-19 백신 접종 후 면역 장수: 현재 승인된 백신에 대한 종합 검토Review Published on 2022-11-302022-09-12 Journal: Human vaccines & immunotherapeutics [Category] MERS, 진단, [키워드] Ad26.COV2.S anti-Spike IgG antibody antibody persistence approved Asymptomatic AZD1222 BNT162b1 BNT162b2 BNT162b2 vaccine BNT162b2 vaccines booster dose Cell-mediated immunity COVID-19 COVID-19 vaccination detectable first dose Humoral immunity IgA antibodies immune response Immunity immunogenicity induce long-term immunity Long-term protection Longevity mRNA-1273 mRNA-1273 vaccine neutralizing effect peaked persistence Perspective produced provide SARS-CoV-2 Spread systematic review T-cell T-cell immunity T-cell Response Vaccine Vaccines [DOI] 10.1080/21645515.2022.2037384 PMC 바로가기 [Article Type] Review
Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2Article Published on 2022-11-012022-11-15 Journal: Cellular and Molecular Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] A570D A701V addition Affect affected antibodies antigenicity B.1.1.529 B.1.1.7 B.1.1.7 lineage B.1.351 B.1.617.2 BALB/c mice binding circulating cross-neutralization activity D1118H decrease Del Delta determine DNA vaccine Effects Efficiency elicited humoral immune response immune evasion immunized immunogen in vitro investigated K417N L18F Lineage Mutation NAbs Naturally neutralization Neutralizing Neutralizing antibodies neutralizing antibody NTD omicron opposite overcome P681H Pseudotyped viruses reduced S982A SARS-CoV-2 SARS-CoV-2 variant sera significantly increased single mutation single mutations spike mutation T cell T cell responses T-cell Response T716I tested the RBD Transmissibility unlikely Vaccine vaccine immunogenicity variants of concern viral entry viral infectivity VoC VOCs was determined weakened [DOI] 10.1038/s41423-022-00924-8 PMC 바로가기
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyArticle Published on 2022-11-012022-11-15 Journal: The Lancet. Gastroenterology & Hepatology [Category] SARS, 진단, [키워드] adjusted age All participant anti-SARS-CoV-2 anti-TNF antibody Antibody binding antibody concentration Antibody concentrations approved available data boost booster case-control study combination therapy Concentration control group COVID-19 COVID-19 vaccine Diagnosis disease dose Evidence first dose geometric mean geometric mean ratio group groups had no healthy control healthy individuals heterologous vaccine homologous IBD Immunosuppressed immunosuppressed patient immunosuppressive Immunosuppressive treatment Infection Inflammatory bowel disease jak inhibitors multicentre multivariable nine no significant difference Older Older age participant Patient patients treated Pfizer Primary outcome receiving Receptor binding domain recipient recruited reduced regimen response S1 RBD SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 vaccination significantly significantly lower Support T-cell Response T-cell responses the healthy therapy Tofacitinib Treatment ulcerative colitis Vaccine vaccine dose vaccine doses vaccine-induced antibody response VIP were measured [DOI] 10.1016/S2468-1253(22)00274-6 PMC 바로가기
Longitudinal survey of humoral and cellular response to SARS-CoV-2 infection in childrenArticle Published on 2022-11-012022-11-15 Journal: Microbiological research [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] Abbott acute infection age analysed anti-RBD IgG antibody antibody blood sample cellular response children COVID-19 decrease diagnosed humoral Humoral response IgG IgG antibodies IgG antibody IgG response immune response Infection longitudinal longitudinal study molecular nasopharyngeal swabs Oxford paediatric patient participant Patient persistence positive SARS-CoV-2 SARS-CoV-2 IgG SARS-COV-2 infection seroconversion rate seroconverted seropositive significant decrease suffered T-cell Response [DOI] 10.1016/j.micres.2022.127145 PMC 바로가기